Navigation Links
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Date:9/5/2008

ary treatment for most subtypes of PTCL remains anthracycline-based regimens, predominantly the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). With the exception of ALK-positive ALCL, PTCL subtypes respond poorly to these regimens. The use of radiotherapy, with or without chemotherapy, is preferred as front line treatment of extranodal NK/T-cell lymphoma. The majority of patients with PTCL will relapse after primary therapy. A number of chemotherapy regimens are used for salvage therapy. However, there is currently no consensus regarding the optimal treatment approach for PTCL salvage therapy.

About Belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade(R) (bortezomib) for injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents. Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal, and ovarian cancers, either alone or in combination with anti- cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. Several trials in the belinostat program are conducted under a Clinical Trail Agreement (CTA) under which the NCI sponsors clinical tri
'/>"/>

SOURCE TopoTarget
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
5. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
8. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
9. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
10. QLT announces positive Health Canada decision on Aczone(R)
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/26/2015)... 2015 Ale Gicqueau, Founder and President ... Clinical Affairs at Align Technology, on “ Conducting Postmarket ... ACRP 2015 Global Conference and Exhibition on April 25th ... , During the poster presentation, Ale Gicqueau and Victor ... a Postmarket Registry, the requirements and resources to conduct ...
(Date:3/25/2015)... is one of the most attractive in the emerging ... a growing economy and increasing government investment in healthcare, ... Russian market is set to grow at twice the ... around 10-15% annually reaching an approximate market value of ... Green Cross provides total healthcare solutions that ...
(Date:3/25/2015)... TORONTO , March 25, 2015 /PRNewswire/ - SQI Diagnostics ... announced that, as a result of recent discussions with ... common shares of the Company, after dealing with certain ... and special meeting of shareholders on March 26, 2015 ... that the election of directors will take place when ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
... April 6, 2012 Arteriocyte, a leading biotechnology ... Massachusetts announced today approval from the Food and ... clinical trial using its Magellan MAR01™ technology in ... Device Exemption (IDE 15013) allows Arteriocyte and its ...
... 2012  GenVec, Inc. (NASDAQ:   GNVC) announced publication ... vectors circumvent neutralizing antibodies in order to generate ... published online in PloS ONE, and can be ... "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing ...
Cached Biology Technology:UK company to demonstrate their commercially effective graphene production process 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 3GenVec Announces Research on Improved Vaccine Vectors 2GenVec Announces Research on Improved Vaccine Vectors 3
(Date:3/10/2015)... , March 10, 2015 Transforming ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured by ... past two years. Specifically, "Personalized Medicine in ... scientific papers published in 2013 and 2014 from Springer ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... In evaluating the bioactive compounds of Illinois blueberry ... compounds that inhibit enzymes responsible for carbohydrate absorption and ... help people with diabetes decrease their blood sugar. ... that would optimize the inhibition of the alpha-amylase and ...
... Philadelphia, PA, August 20, 2012 The more that ... The same can be said about the genetics and ... disease, mutation of a single gene predictably produces a ... to Mendelian disorders, understanding bipolar disorder has been extremely ...
... Hillel was named the 2012 recipient of the World ... have advanced human development by improving the quality, quantity, ... Hillela more than 50-year member of the Soil Science ... the 2012 International Annual Meetings of the American Society ...
Cached Biology News:Drink made from berry wine may provide tasty drug for diabetes 2Making sense out of the biological matrix of bipolar disorder 2World Food Prize winner among speakers at agronomy, crop and soil science societies meetings 2World Food Prize winner among speakers at agronomy, crop and soil science societies meetings 3
... The mycobacteria in Complete Freund's adjuvant ... injection site which enhances the immuneresponse. For ... used for the initial injections; Incomplete Freund's ... Antigens (preferably in saline) are typically mixed ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
...
Biology Products: